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Abstract
Background: Emergence of multi-drug resistant (MDR) serotype 19A Streptococcus pneumoniae
(SPN) is well-documented but causal factors remain unclear. Canadian SPN isolates (1993-2008, n
= 11,083) were serotyped and in vitro susceptibility tested. A subset of MDR 19A were multi-locus
sequence typed (MLST) and representative isolates' whole genomes sequenced.
Results: MDR 19A increased in the post-PCV7 era while 19F, 6B, and 23F concurrently declined.
MLST of MDR 19A (n = 97) revealed that sequence type (ST) 320 predominated. ST320 was unique
amongst MDR 19A in that its minimum inhibitory concentration (MIC) values for penicillin,
amoxicillin, ceftriaxone, and erythromycin were higher than for other ST present amongst post-
PCV7 MDR 19A. DNA sequencing revealed that alleles at key drug resistance loci pbp2a, pbp2x,
pbp2b, ermB, mefA/E, and tetM were conserved between pre-PCV7 ST 320 19F and post-PCV7 ST
320 19A most likely due to a capsule switch recombination event. A genome wide comparison of
MDR 19A ST320 with MDR 19F ST320 identified 822 unique SNPs in 19A, 61 of which were
present in antimicrobial resistance genes and 100 in virulence factors.
Conclusions: Our results suggest a complex genetic picture where high-level drug resistance,
vaccine selection pressure, and SPN mutational events have created a "perfect storm" for the
emergence of MDR 19A.
Background
The introduction of the heptavalent polysaccharide cap-
sule vaccine (PCV7; serotypes 4, 6B, 9V, 14, 18C, 19F, and
23F) in North America as a pediatric universal vaccine
program has led to a significant decrease in vaccine sero-
type invasive pneumococcal disease (IPD) [1] and drug-
resistant pneumococci. However, reports of the vaccine's
success have been tempered by observed increase in the
prevalence of non-vaccine serotypes (NVS) and in partic-
ular the multi-drug resistant (MDR) NVS 19A [2-11].
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Multi-locus sequence typing (MLST) of these isolates has
demonstrated expansion of certain clonal complexes
(CC). The genetic determinants that are driving the suc-
cess of certain CC remain poorly defined. Several plausi-
ble and possibly overlapping hypotheses have been
suggested. The first suggests that MDR 19A is a result of a
genetic recombination event resulting in "capsule switch"
[12,13], thereby giving it a fitness advantage over other
vaccine serotypes by not being subjected to immune selec-
tive pressure. Second, MDR 19A existed before the imple-
mentation of PCV7 and has simply replaced vaccine
serotypes (VS) targeted by PCV7 [14]. Third, MDR 19A
has attained conserved genetic markers which confer
resistance to antibiotics commonly used in the treatment
of Streptococcus pneumoniae (SPN) invasive pneumococcal
disease (IPD) [15]. These genetic markers are missing in
the drug susceptible SPN 19A isolates, such as those
belonging to sequence type 199. Chief amongst these
antibiotics conferred resistance to, are β-lactams and mac-
rolides. Resistance to these drugs likely confers a fitness
advantage to the organism at the population level where
antibiotics are commonly dispensed [15]. Of note, high-
level penicillin resistance has been mainly associated with
serotypes 6A, 6B, 9V, 14, 19A, 19F, and 23F [1]. Successful
expansion of MDR 19A SPN in the post-PCV7 introduc-
tion era poses a serious global public health risk. The hep-
tavalent pneumococcal conjugate vaccine (PCV7, Prevnar,
Wyeth, Madison, NJ) was approved mid-2001 for use in
children in Canada [16]. By early 2006, all provinces and
territories in Canada had instituted this vaccine into their
routine vaccination programs. We describe here the
results of comparative genomics of the emerging multid-
rug resistant serotype 19A identified from 15 years of SPN
serotype and susceptibility testing surveillance in relation
to PCV7 introduction in Canada.
Results
Serotype surveillance and susceptibility testing of MDR 
SPN in the Canadian Bacterial Surveillance Network 
(CBSN) 1993-2008
Serotypes and antibiotic susceptibility testing were deter-
mined for n = 11,083 isolates over a 15 year period. Sero-
type surveillance demonstrated a reduction in vaccine
serotypes from the era immediately prior to PCV7 intro-
duction in Canada (pre-PCV7, 1993-2001), PCV7 intro-
duction era (2002-2005), and post-PCV7 introduction era
(2006-present) (our unpublished data). We focus here on
the MDR serotypes. Figure 1 graphically depicts the trends
in MDR (defined as non-susceptibility to penicillin plus
two other antibiotics) serotypes 6B, 23F, 19F and 19A, the
major contributors to MDR SPN in this population as a
percent of all MDR isolates collected for that year. While
other serotypes contribute to MDR, their numbers were
not significantly large in our database.
Multi-locus sequence typing (MLST) of MDR 19A SPN 
isolates
Due to the rising absolute number of MDR 19A isolates,
MLST was performed to establish the genetic background
of these strains. Figure 2 demonstrates that sequence type
(ST) 320, part of CC271, accounts for the majority of
MDR 19A following the introduction of PCV7 (post-
PCV7) in Canada. Prior to PCV7 introduction, ST320 was
most significantly associated with serotype 19F in this
study (our unpublished data). ST320 is a single-locus var-
iant (different at one gene in the MLST schema compris-
ing seven genes) of Taiwan 19F-14 (ST236) which spread
globally in the pre-PCV7 era [17]. Categorical clustering of
MDR 19A based on MLST demonstrated that ST320 was
associated with high-level penicillin resistance (minimum
inhibitory concentration/MIC ≥ 4 μg/mL) (Figure 3). In
contrast, non-MDR 19A control isolates taken from CBSN
were associated with different STs (Figure 4). Pre-PCV7
MDR 19F high-level penicillin resistance was also strongly
associated with ST320 in our Canadian database (Figure
5). Table 1 to 5 summarize actual MIC values for individ-
ual MDR 19A isolates by ST. MIC values for penicillin
(Table 1), ceftriaxone (Table 2), amoxicillin (Table 3),
erythromycin (Table 4), and ciprofloxacin (Table 5) are
generally higher for ST320 when compared to other STs
amongst MDR 19A. Although not statistically significant,
the most notable trends among these antibiotics were
penicillin and amoxicillin where ST320 was high-level
resistant, while other STs amongst MDR 19A were less
resistant or susceptible. Additional file 1http://www.pil
lailab.com/suppdata/index.html shows eBURST results
and summary statistics for all MLST carried out in this
study. Novel MLST are detailed in Additional file 2http://
www.pillailab.com/suppdata/index.html.
Analysis of antibiotic resistance alleles by DNA sequencing
Mutations associated with elevated minimal inhibitory
concentrations (MIC) have been described for key antibi-
otics commonly used to treat both invasive and non-inva-
sive SPN infection [1,15,18,19]. DNA sequence analysis
for key resistance-conferring residues in penicillin binding
proteins (pbp)  2x, 1a, and 2b  showed conservation
between MDR 19A (this study), MDR 19F (this study),
and MDR 19A from US and Korea (Table 6). However,
residues 339 (F) and 400 (T) of Pbp2x were unique to a
representative MDR 19A in the US and have been associ-
ated with high-level ceftriaxone resistance not seen in
Canadian isolates [10,20]. Susceptible 19A isolates lacked
mutations at key residues in pbp genes which are associ-
ated with β lactam resistance [14]. Similarly, MDR 19A
and 19F had complete conservation at residues of ermB,
mefA,  mef E and  tetM  (all located on the transposon
Tn2010) associated with resistance to macrolides and tet-
racyclines [15]. Identical mutations in Tn2010 were also
observed for representative US and Korea MDR 19A iso-BMC Genomics 2009, 10:642 http://www.biomedcentral.com/1471-2164/10/642
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lates. Genome insertion points of Tn2010 were heteroge-
neous amongst MDR 19A and 19F based on polymerase
chain reaction (PCR) using primers derived from whole
genome sequencing. Additional file 3http://www.pil
lailab.com/suppdata/index.html provides the data set for
all drug resistance gene sequences and Tn2010 insertion
site confirmation results by PCR.
Whole genome sequence of MDR 19A ST320 from the 
post-PCV7 introduction era
A representative isolate of SPN MDR 19A ST320 (Ontario,
2007, sputum isolate from patient with pneumonia) from
the period immediately after universal coverage of PCV7
was identified for whole genome sequencing (WGS). Fig-
ure 6 summarizes the whole genome and each locus can
be navigated in Additional file 4http://www.pil
lailab.com/suppdata/index.html. MDR 19F ST320 from
the pre-PCV7 introduction era (Ontario, 2001, blood iso-
late from patient with sepsis) was also sequenced using
the same method. Sequence comparison of 19F and 19A
ST320 genomes, sequenced and identified 0.41% differ-
ence in AT content and 0.06% difference in GC content
for an overall shared identity of 99.7% between the two
genomes. No evidence of large insertions and deletions
between the two genomes was identified.
Figure 7 provides the breakdown of SNPs unique to MDR
19A ST320. When compared to MDR 19F ST320 and ref-
erence strain R6 (Genbank AE007317), 822 unique SNPs
were identified in the genome of MDR 19A, 169 of which
were non-synonymous [21]. Compared to another sero-
type 19A WGS in Genbank (Hungary 19A-6, NC_010380,
1989, non-invasive), 9484 SNPs were identified. Of the
822 unique SNPs, 61 SNPs (7.4%) were identified in
Serotype trends amongst multi-drug resistant (MDR) strains obtained from the Canadian Bacterial Surveillance Network  between 1993 and 2008 (n = 11,083) Figure 1
Serotype trends amongst multi-drug resistant (MDR) strains obtained from the Canadian Bacterial Surveil-
lance Network between 1993 and 2008 (n = 11,083). MDR 19F (n = 477), 23F (n = 150), and 6B (n = 221) emerged in 
the pre- PCV 7 introduction era (before 2001) and continued to rise during vaccine introduction (2002-2005), then declined in 
post-PCV7 introduction era (2006 onwards). MDR 19A (n = 97) was present in the pre-PCV7 at very low levels and began to 
rise soon after PCV7 was introduced country-wide. Data for 1999 and 2000 were not collected. Data are presented as the 
percent of all MDR isolates collected for the given year.BMC Genomics 2009, 10:642 http://www.biomedcentral.com/1471-2164/10/642
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genes associated with drug resistance and 100 SNPs
(12.1%) in virulence factors. A further 14,208 SNPs were
shared between MDR 19A and 19F ST320, whereas 1536
SNPs were unique to 19F. Of the 61 unique mutations in
antimicrobial resistance genes for MDR 19A, seven were
in the pbp gene family associated with β lactam resistance,
one was in the crcB  family associated with fluoroqui-
nolone resistance, and 53 were in the folate pathway
genes associated with sulfa drug resistance. Unique SNPs
in virulence genes included surface protein pspA precur-
sor (n = 11 SNPs identified in MDR 19A compared to ref-
erence strain R6), determinant for enhanced expression of
pheromone (n = 4) , hyaluronate lyase precursor (n = 4),
unsaturated glucuronyl hydrolase (n = 2), type 2 capsule
locus of SPN (n = 39), choline-binding protein F (n = 5),
choline binding protein A (n = 11), histidine kinase (n =
3), toxin expression - transcriptional accessory protein (n
= 4), pneumococcal histidine triad protein D precursor (n
= 3), immunoglobulin A1 protease (n = 11), N-acetyl-
neuraminate lyase subunit (n = 2), and sialidase B precur-
sor (neuraminidase B) (n = 1). Additional file 5http://
www.pillailab.com/suppdata/index.html details the gene
annotation of unique and shared SNPs (synonymous ver-
sus non-synonymous) for MDR 19A and 19F, genome
location, and functional category. Summary statistics of
the whole genome sequencing can be obtained in Addi-
Multi-locus sequence typing (MLST) of multi-drug resistant (MDR) serotype 19A isolates (n = 97) obtained from the Canadian  Bacterial Diseases Surveillance Network during pre-PCV 7 introduction, vaccine introduction, and post-vaccine introduction  eras Figure 2
Multi-locus sequence typing (MLST) of multi-drug resistant (MDR) serotype 19A isolates (n = 97) obtained 
from the Canadian Bacterial Diseases Surveillance Network during pre-PCV 7 introduction, vaccine introduc-
tion, and post-vaccine introduction eras. Sequence types (ST) are depicted as a percent of all MDR 19 isolates for that 
period. ST320 has emerged as the singular dominant sequence type amongst MDR 19A isolates in the post-PCV7 era. Novel 
implies a collection of strains for which no sequence type (ST) was identified within the MLST http://www.mlst.net/ database at 
this time but submissions have been made and are summarized in Additional file 2. eBURST summary data for MDR 19A, MDR 
19F (n = 30) and susceptible 19A (n = 19) controls are appended in Additional file 1http://www.pillailab.com/suppdata/
index.html.BMC Genomics 2009, 10:642 http://www.biomedcentral.com/1471-2164/10/642
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tional files 6 and 7http://www.pillailab.com/suppdata/
index.html.
Capsule locus sequencing analysis
DNA sequence comparison was carried out for the capsule
locus. Figure 8 depicts the arrangement of genes flanking
the capsule locus which are similar to previously pub-
lished data with some notable exceptions [22,23]. For
example, A 1277 base pair (bp) region encoding the ABC
co-transporter of the vex operon was present adjacent to
the capsule locus in post-PCV7 MDR 19A ST320 but not
in MDR 19F. The vex operon in its entirety was located
outside of the capsule locus for MDR 19F. The vex gene
has homology to ABC co-transporters and has been linked
to vancomycin tolerance in SPN [24]. Of note, β lactam
resistance genes pbp2x and pbp1a were adjacent to the cap-
sule locus and, as summarized in Table 6, harboured key
mutations that confer resistance to β lactam drugs. Align-
ment of pbp1a and pbp2x gene sequences from representa-
tive ST320 MDR 19A (progeny, n = 3), ST320 MDR 19F
(putative recipient, n  = 3), and ST199 19A (putative
donor,  n  = 2) demonstrated one recombination point
located within pbp2x and the other identified by genome
walking distal to pbp1a  (Figure 8 and Additional file
8http://www.pillailab.com/suppdata/index.html). In
contrast to pbp2x where homologous and heterologous
SNPs occur, pbp1a showed perfect conservation between
recipient and donor strains.
Discussion
Serotype surveillance of MDR strains in the CBSN data-
base confirmed what other countries have observed - spe-
cifically the increased prevalence of MDR 19A, with a
concomitant decline in MDR serotypes included in the
PCV7 (6B, 23F, and 19F in our study). MLST analysis of
MDR 19A was able to identify ST320 as the dominant
emerging genotype. This was in contrast to previous stud-
ies [10,13] which demonstrated clonal expansion of an
existing ST199 MDR 19A after PCV7 introduction but in
agreement with other groups [7,8,25]. ST320 appears to
have higher than usual resistance to commonly used anti-
biotics such as penicillin, amoxicillin, and ceftriaxone
based on MIC values and is challenging to treat clinically
especially in the case of bacterial meningitis [25,5]. This
Minimum spanning tree of multi-drug resistant (A) (MDR)  serotype 19A (n = 97) using BioNumerics software Figure 3
Minimum spanning tree of multi-drug resistant (A) 
(MDR) serotype 19A (n = 97) using BioNumerics soft-
ware. A categorical clustering was performed based on 
multi-locus sequence type (MLST). Sequence types sharing 
the maximum number of single-locus variants were con-
nected first. Each circle represents a sequence type (ST) the 
size of which is proportional to the number of isolates within 
that particular ST. Colors within circles indicate the mini-
mum inhibitory concentration (MIC) ranges for penicillin. 
Relationships between the STs are depicted by the lines con-
necting the STs and the relative lengths of the branches link-
ing them. Distance coding enumerates the number of 
differences at a given MLST locus. A distance coding of 
greater than 2 implies a different clonal complex. Angles of 
the line connections and the overlapping circles have no sig-
nificance.
Minimum spanning tree of multi-drug resistant susceptible  19A control isolates (n = 16) using BioNumerics software Figure 4
Minimum spanning tree of multi-drug resistant sus-
ceptible 19A control isolates (n = 16) using BioNu-
merics software. A categorical clustering was performed 
based on multi-locus sequence type (MLST). Sequence types 
sharing the maximum number of single-locus variants were 
connected first. Each circle represents a sequence type (ST) 
the size of which is proportional to the number of isolates 
within that particular ST. Colors within circles indicate the 
minimum inhibitory concentration (MIC) ranges for penicillin. 
Relationships between the STs are depicted by the lines con-
necting the STs and the relative lengths of the branches link-
ing them. Distance coding enumerates the number of 
differences at a given MLST locus. A distance coding of 
greater than 2 implies a different clonal complex. Angles of 
the line connections and the overlapping circles have no sig-
nificance.BMC Genomics 2009, 10:642 http://www.biomedcentral.com/1471-2164/10/642
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may explain in part ST320 expansion under drug selection
pressure. The same genotype and phenotype were present
in MDR 19F in the pre-vaccine era - the major contributor
to ST320 prior to PCV7 introduction in our study. This
was not surprising as 19F ST320 is a single locus variant of
Taiwan 19F-14 which spread globally in the pre-PCV7 era
[26-28]. It was logical then to test the hypothesis that
MDR 19A ST320 emerged from pre-existing MDR 19F
ST320. To lend credence to this hypothesis, it was noted
early on that PCV7 had differential immunological
responses to VS, perhaps allowing certain MDR VS (such
as 19F) to survive and co-circulate with non-VS (such as
19A) during PCV7 introduction in Canada [29]. "Capsule
switch" has been described previously in SPN and would
be the simplest genetic event to account for a 19F to 19A
change [12,30].
Brueggemann and colleagues carried out partial DNA
sequencing at the capsule locus and demonstrated that
recombination points likely lay distal to pbp1a and pbp2x
based on sequence divergence between putative donor,
recipient, and progeny strains [12]. This was an important
demonstration of capsule switch from vaccine serotype 4
(ST695) to non-vaccine serotype 19A (ST199 and ST695)
in the post-PCV7 era [12]. A similar comparison of pbp1a
and pbp2x adjacent to the capsule locus from ST 199 19A
(putative donor), ST 320 MDR 19A (putative progeny),
and 19F (putative recipient) was undertaken in our study.
These data demonstrate definitively that a homologous
recombination event has occurred between donor and
recipient with breakpoint within pbp2x  and flanking
pbp1a, again reinforcing the fact that capsule switch can
Minimum spanning tree of multi-drug resistant MDR 19F iso- lates (n = 29) from the pre-PCV7 era using BioNumerics  software Figure 5
Minimum spanning tree of multi-drug resistant MDR 
19F isolates (n = 29) from the pre-PCV7 era using 
BioNumerics software. A categorical clustering was per-
formed based on multi-locus sequence type (MLST). 
Sequence types sharing the maximum number of single-locus 
variants were connected first. Each circle represents a 
sequence type (ST) the size of which is proportional to the 
number of isolates within that particular ST. Colors within 
circles indicate the minimum inhibitory concentration (MIC) 
ranges for penicillin. Relationships between the STs are 
depicted by the lines connecting the STs and the relative 
lengths of the branches linking them. Distance coding enu-
merates the number of differences at a given MLST locus. A 
distance coding of greater than 2 implies a different clonal 
complex. Angles of the line connections and the overlapping 
circles have no significance.
Table 1: Penicillin minimum inhibitory concentration (MIC, top 
row in bold, μg/mL) values for multi-drug resistant (MDR) 
serotype 19A by sequence type (ST) (n = 97).
SR H R
ST 0.03 0.06 0.12 0.25 0.5 1 2 4 ≥ 8
63 4 1
199 2 11 1
416 3 1
230 2 8 2
276 1 12 2
320 1 22 2
2013 1 2
S, susceptible; I, intermediate; R, resistant; HR, highly resistant.
Table 2: Ceftriaxone minimum inhibitory concentration (MIC, 
top row in bold, μg/mL) values for multi-drug resistant (MDR) 
serotype 19A by sequence type (ST) (n = 97).
SI R
ST 0.03 0.06 0.12 0.25 0.5 1 ≥ 2
63 5
1 9 9 1418
416 3 1
230 2 9
276 2 11 2
320 1 1 23
2013 3
S, susceptible; I, intermediate; R, resistant; HR, highly resistant.
Table 3: Amoxicillin minimum inhibitory concentration (MIC, 
top row in bold, μg/mL) values for multi-drug resistant (MDR) 
serotype 19A by sequence type (ST) (n = 97).
SI R
ST 0.01 0.03 0.06 0.12 0.25 0.5 1 2 4 ≥ 8
63 3 2
199 2 11
416 1 1 1 1
230 3 7 1
230 11 3 1
320 1 1 23
2013 1 1 1
S, susceptible; I, intermediate; R, resistant; HR, highly resistant.BMC Genomics 2009, 10:642 http://www.biomedcentral.com/1471-2164/10/642
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occur between vaccine and non-vaccine serotypes thereby
allowing "vaccine escape". This is a well documented
strategy that SPN employs to enhance its fitness [31,32].
Of interest is the presence of the coding sequence of the
vex  operon (containing an efflux pump ABC co-trans-
porter) associated with vancomycin tolerance adjacent to
the capsule locus of 19A but located in its entirety outside
of this region in 19F. While all strains in this study had an
MIC of ≤ 0.5 μg/mL to vancomycin (our unpublished
data), it is possible that the dysregulation of vex, an ABC-
like transporter, by uncoupling it from the rest of the
operon, could lead to vancomycin MIC creep. Further
evaluation of vancomycin MIC is required to determine
the significance of this gene and its location within the
capsule amongst MDR strains, especially as vancomycin
remains the last line of defense against invasive gram pos-
itive infection [5].
In order to dissect the genome further, we undertook WGS
comparing a representative isolate of ST320 MDR 19A
and 19F. In keeping with the MLST data, near identity
(99.7% across the genome) was observed with 14,208
(86%) shared SNPs, when compared to a reference strain
R6, between MDR 19A and 19F ST320. Of note, MDR 19A
was genetically closer (822 unique SNPs) to MDR 19F in
this study than another serotype 19A from Hungary
present in GenBank (9484 unique SNPs). These data rein-
force that genetic relatedness is better indicated by MLST
rather than serotype. Of the 822 unique SNPs identified in
MDR 19A, some were in drug resistance markers, viru-
lence factors, cell signaling, and key metabolic genes. Of
these, 169 SNPs were non-synonymous. The presence of
unique, non-synonymous SNPs inMDR 19A ST320 sug-
gest that unique polymorphisms may also contribute to
its success in the post-PCV7 era. The presence of muta-
tions in metabolic genes raises the possibility of increased
intrinsic fitness. However, we did not observe significant
difference in growth kinetics between various STs associ-
ated with MDR 19A in liquid culture experiments (our
unpublished data).
South Korea uniquely reported pre-PCV7 MDR 19A
ST320. It remains unclear why MDR 19A would emerge
without vaccine selection pressure against MDR 19F
ST320. Canadian MDR 19A ST320 isolates used in this
study were identical at key drug resistance markers to both
US and Korean representative isolates suggesting a com-
mon source. There was, however, marked heterogeneity of
transposon  Tn2010  insertion sites within a geographic
locale suggesting SPN undergoes rapid modification by
this mode of genetic change. Furthermore, US isolates had
unique mutations which confer high-level resistance to
ceftriaxone and have been associated with other ST. Taken
together, this suggests that MDR 19A emergence has been
caused by distinct genetic events in different geographic
locales rather than global spread of a single clone.
Conclusions
Our data provides evidence that MDR 19A ST320 is genet-
ically derived from MDR 19F ST320 - based on MLST, con-
servation of SNPs across the genome, key drug resistance
markers, and capsule locus structure. However, unique
SNPs and heterogeneous transposition events also existed
in MDR 19A ST320, suggesting that this strain has adapted
and mutated away from a 19F progenitor and is under
Table 4: Erythromycin minimum inhibitory concentration (MIC, top row in bold, μg/mL) values for multi-drug resistant (MDR) 
serotype 19A by sequence type (ST) (n = 97).
SI R
ST 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 ≥ 128
63 113
199 5 1 2 4 1 1
416 4
230 1 9 1 1
276 21 2 1
320 142 0
2013 3
S, susceptible; I, intermediate; R, resistant; HR, highly resistant.
Table 5: Ciprofloxacin minimum inhibitory concentration (MIC, 
top row in bold, μg/mL) values for multi-drug resistant (MDR) 
serotype 19A by sequence type (ST) (n = 97).
SI R
S T 0 . 1 2 0 . 2 5 0 . 5 1 2481 6≥ 32
63 0.5 4 1
199 4 9 1
199 2 1 1
230 1 10
230 14 1
320 1 23 1
2013 1 2
S, susceptible; I, intermediate; R, resistant; HR, highly resistant.BMC Genomics 2009, 10:642 http://www.biomedcentral.com/1471-2164/10/642
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continuous selection pressure. MLST appears to be limited
in explaining the genetic origins of a particular strain as it
focuses only on seven housekeeping genes. We confirm
that PCV7 vaccine selection pressure, antibiotic selection
pressure, and SPN's propensity for genetic change appear
to have created a "perfect storm" for MDR 19A emergence.
Emergence of genetically heterogeneous MDR 19A
appears to be occurring simultaneously in different geo-
graphic locales due to similar selection pressures.
Capsule switch events likely occur through genetic trans-
formation in the nasopharynx of children co-infected
with different ST of SPN. Of great concern to clinicians is
that MDR 19A remains difficult to treat especially in the
case of bacterial meningitis where few therapeutic options
exist to penetrate the cerebrospinal fluid. If as with methi-
cillin resistance Staphylococcus aureus (MRSA) vancomy-
cin creep occurs (rising MIC values), newer antimicrobial
agents will be needed. Furthermore, alternative vaccine
strategies that target all serotypes of SPN (protein based
vaccines) may be prudent in light of this organism's
genetic lability and propensity for vaccine escape. A new
13-valent capsular polysaccharide vaccine (Wyeth, Madi-
son, NJ) is slated for introduction and does include sero-
type 19A and may forestall its spread. Studies in the
developing world are also required to fully understand the
extent of the emergence of this strain.
Methods
Source of isolates
This work has been approved by the Institutional Review
Board of Mt Sinai Hospital, Toronto, Canada. The Cana-
dian Bacterial Surveillance Network is a volunteer group
of private and hospital-affiliated laboratories from across
Canada which has performed surveillance for antibiotic
resistance in Canadian isolates of S. pneumoniae since
1988 [33]. Isolates have been provided from a median of
50 laboratories annually which provide service to com-
munity and tertiary hospitals, as well as community clin-
ics and doctors' offices. All ten provinces were represented
in the sample collection. Laboratories, based on their size
and catchment area, were asked to collect either the first
20 or 100 consecutive clinical isolates each year, as well as
all sterile site isolates, from 1993 to 2008. In this data-
base, 60% were non-sterile and 40% were sterile. Dupli-
cate isolates from the same patient were excluded.
Serotype and susceptibility testing
Serotyping was done by the capsular swelling (quellung)
test, using Danish antisera (State Serum Institute, Copen-
hagen, Denmark) [34]. In vitro susceptibility testing and
interpretation was performed by broth microdilution
according to Clinical and Laboratory Standards Institute
guidelines [35]. The antimicrobial agents were supplied
by their respective manufacturers or were purchased from
Sigma (St. Louis, MO.). Multi-drug resistance (MDR) is
defined as non-susceptible to penicillin plus any two
other classes of antibiotics including macrolides, tetracy-
clines, fluoroquinolones, or trimethoprim-sulfa.
Multi-locus sequence typing DNA sequencing, PCR, and 
whole genome sequencing
MLST was performed according to the standard method
described by Spratt and Enright http://www.mlst.net[36].
Briefly, seven housekeeping gene loci were sequenced
bidirectionally, uploaded to the MLST website, and ana-
lyzed for sequence type and clonal complex associations
based on the existing database. DNA sequencing of genes
Table 6: β-lactam resistance genes pbp1a (penicillin), pbp2b (amoxicillin), and pbp2x (ceftriaxone) from reference strain R6 (Genbank 
AE007317), representative CBSN isolates, US isolates, and South Korean isolates.
Changes in amino acids of conserved PBP sites
pbp 1a pbp 2x pbp 2b
Strain 370-373 428-432 557-559 337-340 394-397 400-401 546-549 385-388 442-445 614-616
19F-14 SAMK KTG SAMK HSSN MS
MOH55 SSMK SRNVT KTG SAMK HSSN MS VKSG SVVK SSNA KTGTG
MOH56 SSMK SRNVT KTG SAMK HSSN MS VKSG SVVK SSNA KTGTG
MOH147 STMK SRNVP KTG SAMK HSSN MT LKSG SVVK SSNA KTGTA
MOH83 SSMK SRNVT KTG SAMK HSSN MS VKSG SVVK SSNA KTGTG
MOH62 SSMK SRNVT KTG SAMK HSSN MS VKSG SVVK SSNA KTGTG
Kor914 SSMK SRNVT KTG SAMK HSSN MS VKSG SVVK SSNA KTGTG
Kor21 SSMK SRNVT KTG SAMK HSSN MS VKSG SVVK SSNA KTGTG
Kor39 SSMK SRNVT KTG SAMK HSSN MS VKSG SVVK SSNA KTGTG
PU1175 SSMK SRNVT KTG SAMK HSSN MS VKSG SVVK SSNA KTGTG
PU6055 SSMK SRNVT KTG SAFK HSSN TS VKSG SVVK SSNA KTGTG
Serotype (SERO), sequence type (ST), clonal complex (CC) and MIC values (mg/mL) for penicillin (PEN), ceftriaxone (CTX) and amoxicillin 
(AMOX) are indicated. Residues associated with resistance to β lactams are in bold letters. Ceftriaxone MIC values for South Korea isolates were 
unavailable. Of note, Taiwan 19F-14 (ST236) [Genbank E043521/E043522] retains residues similar to 19F and 19A in this study at certain residues 
of pbp1a and pbp2x. For the complete data set, including Tn2010-related resistance genes, see Additional file 3.BMC Genomics 2009, 10:642 http://www.biomedcentral.com/1471-2164/10/642
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associated with drug resistance (pbp1a, pbp2b, pbp2x, tetR
and ermB) was performed using a standard capillary gene
sequencer from Applied Biosystems (Foster City, CA). The
Solexa paired-end Sequencing Platform (Illumina, San
Diego, CA) was used to generate reads of 50 to 75 bp
(with on average greater than 100X coverage for the
genome) which were assembled using NextGene (SoftGe-
netics, State College, PA). [37]. Annotation of the genome
was performed using the RAST (Rapid Annotation using
Subsystem Technology) server [38]. Additional file 9http:/
/www.pillailab.com/suppdata/index.html summarizes all
polymerase chain reaction (PCR) and DNA sequencing
primers and associated cycling parameters used in this
study to confirm WGS findings at the capsule locus, resist-
ance alleles, and transposon insertion sites.
The whole genome sequence of a representative CBSN isolate of emergent multi-drug resistant serotype 19A ST320 (Gen- bank Accession GPID ACNU00000000) was compared to a representative isolate of 19F ST320 from the pre-vaccine era  (Genbank Accession GPID ACNV00000000) Figure 6
The whole genome sequence of a representative CBSN isolate of emergent multi-drug resistant serotype 19A 
ST320 (Genbank Accession GPID ACNU00000000) was compared to a representative isolate of 19F ST320 
from the pre-vaccine era (Genbank Accession GPID ACNV00000000). The Solexa platform (Illumina Inc, San Diego, 
CA) was used for sequencing with greater than 100X coverage obtained throughout each genome. Depicted here is the whole 
genome of a representative MDR 19A ST320 in the post-vaccine era. The locations of proteins encoded on the leading and lag-
ging strands are shown on the outer two rings. Gene ontology categories are color-coded. Of the internal ring, the outermost 
bars indicate SNPs identified in the leading strand and the innermost bars represent SNP identified in the lagging strand relative 
to MDR 19F ST320. The length of the bars is propostional to the number of SNPs. For detailed gene identification, location of 
capsule biosynthetic loci, other key alleles, comparison of 19A and 19F SNPs, as well as a mutation profile compared to refer-
ence strain R6 (Genbank AE007317), see Additional file 4http://www.pillailab.com/suppdata/index.html.BMC Genomics 2009, 10:642 http://www.biomedcentral.com/1471-2164/10/642
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Pie chart percentage breakdown by gene ontology classification (GenoList, Institut Pasteur, Paris) of single nucleotide polymor- phisms (SNPs) belonging to MDR 19A ST320 relative to MDR 19F ST320 Figure 7
Pie chart percentage breakdown by gene ontology classification (GenoList, Institut Pasteur, Paris) of single 
nucleotide polymorphisms (SNPs) belonging to MDR 19A ST320 relative to MDR 19F ST320.
Alignment of the capsular biosynthetic loci between ST320 MDR19A in the post-PCV7 introduction era and pre-PCV7  MDR19F Figure 8
Alignment of the capsular biosynthetic loci between ST320 MDR19A in the post-PCV7 introduction era and 
pre-PCV7 MDR19F. The capsule locus resides between genes aliA and dexB. The vex operon was present directly adjacent to 
the capsule locus of 19A but not 19F. Of note are the genes pbp2x and pbp1a, responsible for penicillin resistance, that are 
present adjacent to the capsule locus. For a full image of the capsule locus and flanking regions please see Additional file 8http:/
/www.pillailab.com/suppdata/index.html.BMC Genomics 2009, 10:642 http://www.biomedcentral.com/1471-2164/10/642
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Bioinformatic analysis
eBURST analysis of MLST sequence data was performed as
described on the MLST website http://www.mlst.net[39].
Genome assembly was performed using NextGene (Soft-
Genetics, State College, PA) and genome comparison
using the Artemis Comparison Tool (Wellcome Trust
Sanger Institute, Cambridge, UK). Gene ontology classifi-
cation was achieved using GenoList (Institut Pasteur,
Paris). Gene ontology categories were identified using
AmiGO [21].
Data Submission and Analysis
This Whole Genome Shotgun project has been deposited
at DDBJ/EMBL/GenBank under the accession
ACNU00000000 (Streptococcus pneumoniae str. Canada
MDR_19A identified in Ontario, Canada in 2007) and
ACNV00000000 (Streptococcus pneumoniae str. Canada
MDR_19F identified in Ontario, Canada in 2001). This
paper describes the first versions of the whole genome for
Canada MDR_19A (ACNU10000000) and MDR_19F
(ACNV10000000). Detailed statistics about the genome
sequences and the assembly, coverage and distribution
reports as well as a summary of the SNP profiles is pro-
vided in Additional files 6 and 7. Novel MLST allele sub-
mission numbers are summarized in Additional file 2.
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Additional file 1
The complete MLST data set, summary statistics and eBURST figures. 
http://www.mlst.net. eBURST figures can be obtained by clicking on the 
hyperlinks. Figures are presented for MDR 19A, control 19A and 19F iso-
lates referred to in the text, as well as isolates based on era (pre-PCV7, 
PCV7, and post-PCV7). All supplementary data can also be accessed at 
the following website http://www.pillailab.com/suppdata/index.html
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2164-10-642-S1.XLS]
Additional file 2
New MLST sequence type and submission numbers identified in this 
study.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2164-10-642-S2.XLS]
Additional file 3
Complete data set for β lactam (pbp), erythromycin (erm), and tet-
racycline (tet) resistance gene mutation alleles. Sequence analysis of 
Tn2010 insertion sites was based on primers designed from the WGS. A 
(+) indicated amplification and (-) no amplification by PCR for each iso-
late tested using primers derived from the WGS. These data demonstrated 
heterogeneity amongst MDR ST320 19A and MDR 19F isolates in the 
pre-PCV7 era with some common insertion points between serotypes. 
Tn2010 constituent genes ermB, mefA, tetM, and mega were highly 
conserved amongst post-PCV7 MDR 19A and pre-PCV7 MDR 19F.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2164-10-642-S3.XLS]
Additional file 4
The annotated whole genome sequence data set for representative iso-
lates of MDR 19A ST320. The first tab shows the full gene listing. To 
zoom in on a portion of the genome, click on the circular genome at the 
location of interest. The lower panel of the first tab depicts the entire cap-
sule locus and flanking genes. The second tab gives the full mutation pro-
file. The third tab gives the functional categories present in the genome.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2164-10-642-S4.XLS]
Additional file 5
Mutation report of all single nucleotide polymorphisms, genomic loca-
tion, and their gene ontology classification. Specific data for MDR 19F 
(tab 1), 19A (tab 2), and both (tab 3), relative to reference strain R6 
(Genbank AE007317) are shown. Unique SNPs for 19F (tab 4) and 19A 
(tab 5) and subsequent analysis (tab 6) are alsolisted.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2164-10-642-S5.XLS]
Additional file 6
Whole genome statistics, SNP summary, distribution and coverage report 
of the genomes for MDR 19A
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2164-10-642-S6.DOC]
Additional file 7
Whole genome statistics, SNP summary, distribution and coverage report 
of the genomes for MDR 19A
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
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